CN101066472B - Tissue engineered peripheral nerve graft and preparation method thereof - Google Patents
Tissue engineered peripheral nerve graft and preparation method thereof Download PDFInfo
- Publication number
- CN101066472B CN101066472B CN 200710039573 CN200710039573A CN101066472B CN 101066472 B CN101066472 B CN 101066472B CN 200710039573 CN200710039573 CN 200710039573 CN 200710039573 A CN200710039573 A CN 200710039573A CN 101066472 B CN101066472 B CN 101066472B
- Authority
- CN
- China
- Prior art keywords
- cells
- hair follicle
- tissue
- neural crest
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000578 peripheral nerve Anatomy 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 65
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 49
- 210000005036 nerve Anatomy 0.000 claims abstract description 38
- 210000001519 tissue Anatomy 0.000 claims abstract description 22
- 210000000130 stem cell Anatomy 0.000 claims abstract description 21
- 210000000933 neural crest Anatomy 0.000 claims abstract description 20
- 210000002469 basement membrane Anatomy 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 7
- 230000006698 induction Effects 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 9
- 238000010276 construction Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 241000289669 Erinaceus europaeus Species 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- 229960001727 tretinoin Drugs 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102000014413 Neuregulin Human genes 0.000 claims 2
- 108050003475 Neuregulin Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 13
- 230000007547 defect Effects 0.000 abstract description 10
- 230000001537 neural effect Effects 0.000 abstract description 9
- 230000008929 regeneration Effects 0.000 abstract description 9
- 238000011069 regeneration method Methods 0.000 abstract description 9
- 108010056384 CDPGYIGSR Proteins 0.000 abstract description 7
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000012568 clinical material Substances 0.000 abstract 1
- 210000003050 axon Anatomy 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 210000003497 sciatic nerve Anatomy 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 210000001178 neural stem cell Anatomy 0.000 description 7
- 210000004116 schwann cell Anatomy 0.000 description 7
- 230000008439 repair process Effects 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 102000048238 Neuregulin-1 Human genes 0.000 description 4
- 108090000556 Neuregulin-1 Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003135 vibrissae Anatomy 0.000 description 2
- XQQUSYWGKLRJRA-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical group CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XQQUSYWGKLRJRA-RABCQHRBSA-N 0.000 description 1
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical group NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 208000020538 atrophic muscular disease Diseases 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000013228 contact guidance Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
本发明涉及生物组织工程技术领域,具体涉及一种修复神经缺损移植用的组织工程化周围神经及其制备方法。本发明提供的组织工程化周围神经移植体,其中的种子细胞是以毛囊神经嵴干细胞(NCSC)诱导分化的神经元样细胞和类施万细胞的混合细胞,其中的支架是以寡肽CDPGYIGSR和CQAASIKVAV修饰的异种去细胞神经基膜管。本发明还提供了上述组织工程化周围神经移植体的制备方法。本发明内的种子细胞尤其是神经元样细胞对神经再生有更好的促进作用,为临床提供一种材料来源广泛、无免疫原性、不涉及伦理学问题、修复长段神经缺损效果更好的组织工程化神经移植体。The invention relates to the technical field of biological tissue engineering, in particular to a tissue-engineered peripheral nerve for repairing nerve defect transplantation and a preparation method thereof. In the tissue-engineered peripheral nerve graft provided by the present invention, the seed cells are mixed cells of neuron-like cells and Schwann-like cells induced to differentiate by hair follicle neural crest stem cells (NCSC), and the scaffolds are based on oligopeptides CDPGYIGSR and CQAASIKVAV modified xenogeneic decellularized neural basement membrane tubes. The present invention also provides a preparation method of the tissue engineered peripheral nerve graft. The seed cells in the present invention, especially the neuron-like cells, have a better effect on promoting nerve regeneration, and provide clinical materials with a wide range of sources, no immunogenicity, no ethical issues involved, and better effects in repairing long-segment nerve defects tissue engineered neural grafts.
Description
技术领域technical field
本发明涉及生物组织工程技术领域,具体涉及一种修复神经缺损移植用的组织工程化周围神经及其制备方法。The invention relates to the technical field of biological tissue engineering, in particular to a tissue-engineered peripheral nerve for repairing nerve defect transplantation and a preparation method thereof.
背景技术Background technique
周围神经再生的基本生物学特性为:周围神经损伤后,远端神经发生瓦勒变性,近端轴突发出的轴芽在间充质细胞的间隙向前滑行,长到远端的Büngner带中,并向靶器官生长形成突触连接;施万细胞使轴突髓鞘化;恢复神经结构,完成神经再生的过程。The basic biological characteristics of peripheral nerve regeneration are: after peripheral nerve injury, Wallerian degeneration occurs in the distal nerve, and the axon sprouts from the proximal axons slide forward in the gap between mesenchymal cells and grow to the distal Büngner zone. and grow to the target organ to form synaptic connections; Schwann cells myelinate the axons; restore the nerve structure and complete the process of nerve regeneration.
目前国内外组织工程化周围神经均是依据周围神经再生的基本生物学特性而设计的。它们有一特定的三维结构支架-神经导管,可接纳再生轴突长入,对轴突起机械引导作用;种植的施万细胞在支架内有序地分布,类似Büngner带;施万细胞具有生物活性,能分泌神经营养因子,造成一个轴突生长的微环境,支持引导轴突的再生。但是在这种思路下构建的组织工程化神经,由于受神经趋化和接触引导的限制,桥接的距离一般不超过30mm,而临床上面临的主要问题是长段缺损时自体神经的来源不足;轴突再生需跨越两个吻合口,增加了神经再生的难度;另外,新生轴突生长时间的过长及在生长过程中的误入,易出现效应器的废用性萎缩或神经-效应器失配等。这些问题制约了组织工程化神经的临床应用。At present, tissue-engineered peripheral nerves at home and abroad are designed based on the basic biological characteristics of peripheral nerve regeneration. They have a specific three-dimensional structure scaffold-nerve conduit, which can accept the growth of regenerated axons and play a role in mechanically guiding the axons; the planted Schwann cells are distributed in an orderly manner in the scaffold, similar to Büngner's belt; Schwann cells have biological activity, Can secrete neurotrophic factors, create a microenvironment for axonal growth, support and guide axonal regeneration. However, the tissue-engineered nerves constructed under this idea are limited by nerve chemotaxis and contact guidance, and the bridging distance generally does not exceed 30 mm. The main problem in clinical practice is that the source of autologous nerves is insufficient in long-segment defects; Axon regeneration needs to span two anastomoses, which increases the difficulty of nerve regeneration; in addition, the growth time of new axons is too long and they enter by mistake during the growth process, which is prone to disuse atrophy of effector or nerve-effector Mismatch etc. These problems restrict the clinical application of tissue engineered nerves.
2003年,Stephen等将脊髓分离的神经干细胞移植于横断的大鼠坐骨神经远断端,发现神经干细胞转化为运动神经元样细胞,并伸出轴突进入肌肉,形成胆碱能突触。受该研究的启发,为解决目前组织工程化神经的不足,本发明以神经元为主要细胞构建组织工程化周围神经,利用桥接神经元的方法重建缺损神经功能的思路和方法,可以克服诱导性组织工程化神经桥接距离较短、轴突再生需跨越两个吻合口和新生轴突生长时间过长的问题。In 2003, Stephen et al. transplanted neural stem cells isolated from the spinal cord to the distal stump of the transected rat sciatic nerve, and found that the neural stem cells transformed into motor neuron-like cells, and extended axons into muscles to form cholinergic synapses. Inspired by this study, in order to solve the deficiencies of the current tissue-engineered nerves, the present invention uses neurons as the main cells to construct tissue-engineered peripheral nerves, and uses the idea and method of bridging neurons to reconstruct the defective nerve function, which can overcome the inductive The bridging distance of tissue-engineered nerves is short, axon regeneration needs to span two anastomoses and the growth time of new axons is too long.
构建组织工程的关键因素是种子细胞,目前在组织工程化神经构建中研究较多的种子细胞是施万细胞、骨髓间充质干细胞和神经干细胞等。自体外周施万细胞为终末期细胞,存在增殖能力差,体外分离、培养困难和活性下降,需二次手术等缺点,虽经基因修饰得到了施万细胞的永生株,但其分泌利于神经修复因子的能力也显著下降;异体移植常面临免疫排斥反应。骨髓间充质干细胞具有取材方便、扩增迅速,避免了异体神经移植所致的免疫排斥反应等优点,但诱导分化成神经元样细胞的比率相对较低。神经干细胞作为组织工程化神经新的种子细胞,是近年来的研究热点,但自体神经干细胞来源困难,异体神经干细胞同样有免疫排斥反应问题。因此,寻找新的种子细胞应是组织工程化神经构建的当务之急。The key factor in constructing tissue engineering is seed cells. Currently, the seed cells that have been studied more in tissue engineering neural construction are Schwann cells, bone marrow mesenchymal stem cells, and neural stem cells. Autologous peripheral Schwann cells are end-stage cells with poor proliferative ability, difficulty in in vitro isolation and culture, decreased activity, and the need for a second operation. Although the immortal strain of Schwann cells has been obtained through genetic modification, its secretion is conducive to nerve repair. The ability of factor is also significantly decreased; allograft often faces immune rejection. Bone marrow mesenchymal stem cells have the advantages of convenient extraction, rapid expansion, and avoidance of immune rejection caused by allogeneic nerve transplantation, but the rate of induction into neuron-like cells is relatively low. Neural stem cells, as new seed cells for tissue engineered nerves, have been a research hotspot in recent years, but the source of autologous neural stem cells is difficult, and allogeneic neural stem cells also have the problem of immune rejection. Therefore, finding new seed cells should be the top priority for tissue engineering neural construction.
Sieber-Blum等的研究表明,在成体毛囊隆突内存在着多潜能的干细胞,而且是神经嵴来源的,故将其命名为毛囊神经嵴干细胞(NCSC),它可自然分化为神经元、平滑肌细胞、SC及黑素细胞等。Amoh等研究发现毛囊隆突部干细胞表现为巢蛋白(Nestin)阳性,能形成神经元,经10%胎牛血清诱导分化后,有近一半的细胞分化为神经元(48%),30%的细胞分化为神经胶质细胞,还有其他细胞如角质细胞(18%)、平滑肌细胞(2%)、黑素细胞(2%)等,而且将这些Nestin阳性的毛囊干细胞移植至小鼠坐骨神经缺损处可使其转分化为施万细胞,对神经缺损起到了较好的修复作用。可见,毛囊NCSC可来源于自身,取材方便,损伤小,不涉及免疫原性和伦理学问题,并具备向神经细胞分化的优势。The research of Sieber-Blum et al. showed that there are pluripotent stem cells in the adult hair follicle bulge, and they are derived from the neural crest, so they are named hair follicle neural crest stem cells (NCSC), which can naturally differentiate into neurons and smooth muscles. cells, SC and melanocytes, etc. Amoh et al. found that stem cells in the hair follicle bulge were positive for Nestin and could form neurons. After being induced and differentiated by 10% fetal bovine serum, nearly half of the cells differentiated into neurons (48%), and 30% of the cells differentiated into neurons. Cells differentiated into glial cells, and other cells such as keratinocytes (18%), smooth muscle cells (2%), melanocytes (2%), etc., and these Nestin-positive hair follicle stem cells were transplanted into mouse sciatic nerve defects It can make it transdifferentiate into Schwann cells, and play a good role in repairing nerve defects. It can be seen that hair follicle NCSC can be derived from itself, which is convenient to obtain, has little damage, does not involve immunogenicity and ethical issues, and has the advantage of differentiating into nerve cells.
支架材料是决定组织工程神经能否成功构建和应用于临床的又一关键。Yu等研究表明层粘连蛋白(参见Biomaterials,2005,26(13):1507-1514.)是一种可增强细胞粘附、迁移、分化和基因表达的细胞外基质,位于其β1链的YIGSR序列可增强神经细胞的粘附力,位于A链上的IKVAV序列可促进神经细胞的轴突生长,延长的氨基酸序列CDPGYIGSR和CQAASIKVAV则能进一步增强细胞的粘附力和促进轴突的生长。Scaffold materials are another key to determine whether tissue engineered nerves can be successfully constructed and applied clinically. Yu et al. showed that laminin (see Biomaterials, 2005, 26(13): 1507-1514.) is an extracellular matrix that can enhance cell adhesion, migration, differentiation and gene expression, and the YIGSR sequence located in its β1 chain It can enhance the adhesion of nerve cells. The IKVAV sequence located on the A chain can promote the axon growth of nerve cells. The extended amino acid sequence CDPGYIGSR and CQAASIKVAV can further enhance the adhesion of cells and promote the growth of axons.
发明内容Contents of the invention
本发明的目的在于提供一种材料来源广泛、活性强、无免疫原性、不涉及伦理学问题、可修复长段神经缺损的组织工程化周围神经移植体,及其制备方法。The object of the present invention is to provide a tissue-engineered peripheral nerve graft that can repair long-segment nerve defects, and a preparation method thereof, with wide material sources, strong activity, no immunogenicity, no ethical issues involved, and the ability to repair long-segment nerve defects.
本发明提供一种组织工程化周围神经移植体,包括种子细胞和支架,其中的种子细胞是以毛囊神经嵴干细胞(NCSC)诱导分化的神经元样细胞和类施万细胞的混合细胞,其中的支架是以具有SEQ ID NO:1和SEQID NO:2所示氨基酸序列的寡肽修饰的异种去细胞神经基膜管。The present invention provides a tissue engineered peripheral nerve graft, comprising seed cells and scaffolds, wherein the seed cells are mixed cells of neuron-like cells and Schwann-like cells induced to differentiate from follicular neural crest stem cells (NCSC), wherein The scaffold is a heterogeneous decellularized neural basement membrane tube modified with oligopeptides having the amino acid sequences shown in SEQ ID NO: 1 and SEQ ID NO: 2.
本发明提供一种组织工程化周围神经移植体的制备方法,包括毛囊神经嵴干细胞(NCSC)的分离、培养、纯化、扩增和鉴定;毛囊NCSC向神经元样和类施万细胞的诱导分化及鉴定;异种去细胞神经基膜管支架的制备及修饰;神经元性组织工程化周围神经的体外构建。The invention provides a preparation method of tissue-engineered peripheral nerve grafts, including the separation, cultivation, purification, expansion and identification of hair follicle neural crest stem cells (NCSC); the induction and differentiation of hair follicle NCSC to neuron-like and Schwann-like cells and identification; preparation and modification of xenogeneic decellularized nerve basement membrane tube scaffolds; in vitro construction of neuronal tissue engineered peripheral nerves.
具体步骤如下:Specific steps are as follows:
1.制备成体毛囊神经嵴干细胞(NCSC)1. Preparation of adult hair follicle neural crest stem cells (NCSC)
按贴块法从成年毛囊隆突部分离获得毛囊NCSC(参见Sieber-Blum等,Developmental Dynamics,2004,231:258-269.)。取清洁级SD大鼠触须垫皮肤毛囊隆突部,于神经干细胞培养液中贴块培养,传代培养获得毛囊NCSC。Hair follicle NCSCs were isolated from adult hair follicle bulges by the patch method (see Sieber-Blum et al., Developmental Dynamics, 2004, 231: 258-269.). The skin hair follicle bulge of the vibrissa pad of clean SD rats was taken, cultured as a block in neural stem cell culture medium, and subcultured to obtain hair follicle NCSC.
2.成体毛囊NCSC的诱导分化2. Induction and differentiation of adult hair follicle NCSC
以维甲酸RA(5~20μmol/L;购自Sigma)和hedgehog激动剂(hedgehogagonist,HhAg1.3,5~20μmol/L;购自Curis Inc.)联合诱导毛囊NCSC,使之分化为神经元样细胞。最佳诱导浓度为10μmol/L。作用时间为1d~14d,最佳作用时间为7d。Retinoic acid RA (5-20 μmol/L; purchased from Sigma) and hedgehog agonist (hedgehogagonist, HhAg1.3, 5-20 μmol/L; purchased from Curis Inc.) were combined to induce hair follicle NCSC to differentiate into neuron-like cell. The best induction concentration is 10μmol/L. The action time is 1d to 14d, and the best action time is 7d.
以神经调节蛋白neuregulin-1(NRG1,50~150ng/ml,购自Sigma)诱导毛囊NCSC,使之分化为类施万细胞。最佳诱导浓度为100ng/ml。作用时间为1d~14d,最佳作用时间为7d。Hair follicle NCSCs were induced to differentiate into Schwann-like cells with neuregulin-1 (NRG1, 50-150 ng/ml, purchased from Sigma). The best induction concentration is 100ng/ml. The action time is 1d to 14d, and the best action time is 7d.
3.异种去细胞神经基膜管支架的制备及修饰3. Preparation and Modification of Xenogeneic Decellularized Basement Membrane Tube Scaffolds
以1%溶血卵磷脂等处理犬坐骨神经,获得异种去细胞神经基膜管支架。并以寡肽CDPGYIGSR(SEQ ID NO:1)、CQAASIKVAV(SEQ IDNO:2)按1∶1的比例联合浸泡支架,最佳浸泡时间是12小时,低压冻干,环氧乙烷灭菌,-20℃保存备用。The canine sciatic nerve was treated with 1% lysolecithin, etc. to obtain the heterogeneous decellularized nerve basement membrane tube scaffold. And the oligopeptide CDPGYIGSR (SEQ ID NO: 1), CQAASIKVAV (SEQ ID NO: 2) was combined to soak the scaffold in a ratio of 1:1, the optimal soaking time was 12 hours, lyophilized, ethylene oxide sterilized, - Store at 20°C for later use.
4.体外构建神经元性组织工程化周围神经4. Construction of neuronal tissue engineered peripheral nerves in vitro
在手术显微镜下分别按1∶1、2∶1、3∶1的比例种植毛囊NCSC诱导分化的神经元样细胞和类施万细胞,将复合了种子细胞的异种去细胞神经基膜管支架置于旋转培养腔内进行体外构建。Under the operating microscope, neuron-like cells and Schwann-like cells induced and differentiated by hair follicle NCSC were planted at a ratio of 1:1, 2:1, and 3:1, respectively, and the heterogeneous decellularized neural basement membrane tube scaffold compounded with seed cells was placed. In vitro construction was carried out in a rotating culture chamber.
本发明的种子细胞选材于毛囊神经嵴干细胞(NCSC),不仅可来源于自身,而且来源广泛、取材方便,损伤小、活性强、不涉及免疫原性和伦理学问题,NCSC诱导的神经元样细胞对神经再生有更好的促进作用;本发明以寡肽CDPGYIGSR和CQAASIKVAV联合修饰支架材料更有利于种子细胞的粘附、迁移和分化。The seed cells of the present invention are selected from hair follicle neural crest stem cells (NCSC), which can not only be derived from themselves, but also have a wide range of sources, convenient material collection, small damage, strong activity, and no immunogenicity and ethical issues. NCSC-induced neuron-like Cells have a better promoting effect on nerve regeneration; in the present invention, the oligopeptide CDPGYIGSR and CQAASIKVAV are combined to modify the scaffold material, which is more conducive to the adhesion, migration and differentiation of seed cells.
具体实施方式Detailed ways
现结合实施例,对本发明作进一步的描述,但本发明的实施并不仅限于此。Now, the present invention will be further described in conjunction with the embodiments, but the implementation of the present invention is not limited thereto.
实施例1:Example 1:
1.制备成体毛囊神经嵴干细胞(NCSC)1. Preparation of adult hair follicle neural crest stem cells (NCSC)
(1)毛囊NCSC的原代培养(1) Primary culture of hair follicle NCSC
清洁级SD大鼠,体质量100g,颈椎脱臼处死。75%乙醇消毒,取大鼠触须垫毛囊,室温、显微镜下、无菌条件,每只大鼠取10~20个毛囊,以供制备1~2条组织工程神经用。完整毛囊置于4℃DPBS中,剪去毛囊球部,剥除毛囊外层结缔组织囊,暴露毛囊隆突部(保留毛干1mm,便于贴块操作),以4℃DPBS清洗2遍,备用。每35mm培养皿均匀涂布鼠尾胶(1mg/ml,购自Sigma)50μl,室温置超净台干燥1h以上,置于37℃、5%CO2培养箱中以原代培养液孵育3h备用。每35mm培养皿种植5~8个毛囊隆突,于37℃、5%CO2培养箱中静置1h后,再缓慢加入原代培养液[DMEM/F12(1∶1),购自GIBCO;B27(2%),购自GIBCO;N2(1%),购自GIBCO;ITS+3(insulin,transferrin,selenium,andthree essential fatty acids),购自Sigma;bFGF(20ng/ml),EGF(20ng/ml);L-谷氨酰胺(200μmol/L);胎牛血清(10%),购自GIBCO],静置培养4~6天后传代培养。Clean grade SD rats, weighing 100 g, were sacrificed by cervical dislocation. Disinfect with 75% ethanol, take rat vibrissa pad hair follicles, at room temperature, under a microscope, under sterile conditions, take 10-20 hair follicles from each rat, for preparing 1-2 tissue-engineered nerves. Put the complete hair follicle in 4°C DPBS, cut off the hair follicle bulb, peel off the outer connective tissue of the hair follicle, and expose the hair follicle bulge (keep the hair shaft 1mm, which is convenient for block operation), wash 2 times with 4°C DPBS, and set aside . 50 μl of rat tail gum (1 mg/ml, purchased from Sigma) was evenly coated on each 35 mm culture dish, dried on a clean bench at room temperature for more than 1 h, and incubated with the primary culture medium in a 37° C., 5% CO2 incubator for 3 h for later use. Plant 5-8 hair follicle protuberances per 35mm culture dish, let it stand in a 37°C, 5% CO2 incubator for 1 hour, and then slowly add the primary culture medium [DMEM/F12 (1:1), purchased from GIBCO; B27 (2%), purchased from GIBCO; N2 (1%), purchased from GIBCO; ITS+3 (insulin, transferrin, selenium, and three essential fatty acids), purchased from Sigma; bFGF (20ng/ml), EGF (20ng/ ml); L-glutamine (200 μmol/L); fetal bovine serum (10%), purchased from GIBCO], cultured statically for 4 to 6 days and then subcultured.
(2)毛囊NCSC的传代培养(2) Subculture of hair follicle NCSC
以显微器械剔除毛囊隆突,0.25%胰酶消化2min,胰酶抑制剂终止消化,每35mm皿加入2ml培养液(不含胎牛血清,其余成分同原代培养液),以吸管吹打制备单细胞悬液,细胞密度为1×105/ml。37℃、5%CO2培养箱中静置培养,每两天换半液。Remove hair follicle protrusions with microscopic instruments, digest with 0.25% trypsin for 2 minutes, stop digestion with trypsin inhibitor, add 2ml of culture medium (without fetal bovine serum, the rest of the ingredients are the same as the original culture medium) per 35mm dish, and pipette to prepare Single cell suspension, the cell density is 1×10 5 /ml. Culture in a 37°C, 5% CO 2 incubator, and change half of the solution every two days.
2.成体毛囊NCSC的诱导分化2. Induction and differentiation of adult hair follicle NCSC
(1)向神经元样细胞的诱导分化(1) Induced differentiation into neuron-like cells
取第2代毛囊NCSC,加入10μmol/L维甲酸RA(Sigma)和10μmol/Lhedgehog激动剂(hedgehog agonist,HhAg1.3,Curis Inc.),作用时间为7d。The second-generation hair follicle NCSCs were taken, and 10 μmol/L retinoic acid RA (Sigma) and 10 μmol/L hedgehog agonist (hedgehog agonist, HhAg1.3, Curis Inc.) were added for 7 days.
(2)向类施万细胞的诱导分化(2) Induced differentiation to Schwann-like cells
取第2代毛囊NCSC,以100ng/ml neuregulin-1(NRG1,Sigma)诱导分化,作用时间为7d,之后进行类施万细胞的鉴定。The second-generation hair follicle NCSCs were taken and differentiated with 100ng/ml neuregulin-1 (NRG1, Sigma) for 7 days, after which Schwann-like cells were identified.
3.异种去细胞神经基膜管支架的制备及修饰3. Preparation and Modification of Xenogeneic Decellularized Basement Membrane Tube Scaffolds
委托上海生工生物工程有限公司合成寡肽CDPGYIGSR(SEQ ID NO:1)、CQAASIKVAV(SEQ ID NO:2)。Entrust Shanghai Sangon Bioengineering Co., Ltd. to synthesize oligopeptides CDPGYIGSR (SEQ ID NO: 1) and CQAASIKVAV (SEQ ID NO: 2).
无菌条件下取犬坐骨神经,DPBS(pH 7.3)4℃,5d,1%溶血卵磷脂/0.1mol/L PBS(pH 7.0),室温,4d,每隔24h换液1次,DPBS洗30min,DNase I(600U/ml)、RNase A(10U/ml),37℃,24h,DPBS洗3次,1h,寡肽CDPGYIGSR/CQAASIKVAV(1∶1,1.5mg/ml,溶于PBS中)浸泡12h,其间轻微振动。PBS充分漂洗3次,低压冻干,环氧乙烷灭菌,-20℃保存备用。Canine sciatic nerve was collected under sterile conditions, DPBS (pH 7.3) at 4°C for 5 days, 1% lysolecithin/0.1mol/L PBS (pH 7.0), at room temperature for 4 days, the medium was changed once every 24 hours, and washed with DPBS for 30 minutes. DNase I (600U/ml), RNase A (10U/ml), 37°C, 24h, washed 3 times with DPBS, 1h, oligopeptide CDPGYIGSR/CQAASIKVAV (1:1, 1.5mg/ml, dissolved in PBS) soaked for 12h , during which there is a slight vibration. Rinse thoroughly with PBS three times, lyophilize at low pressure, sterilize with ethylene oxide, and store at -20°C for later use.
4.体外构建神经元性组织工程化周围神经4. Construction of neuronal tissue engineered peripheral nerves in vitro
种子细胞的种植密度为1×106/ml~1×107/ml,在手术显微镜下,分别按1∶1、2∶1、3∶1的比例种植毛囊NCSC诱导分化的神经元样细胞和类施万细胞。The planting density of the seed cells is 1×10 6 /ml~1×10 7 /ml, and under the operating microscope, the neuron-like cells induced by hair follicle NCSC are planted at the ratio of 1:1, 2:1, and 3:1, respectively. and Schwann-like cells.
先显微注射(显微手术镜下以微量加样器将种子细胞混合悬液注射入支架,间隔5mm,每次注射20~50μl),后浸润接种(将种子细胞混合悬液均匀地滴加于支架上,在培养皿内悬空孵育4h),再旋转培养(将支架固定于旋转培养腔内培养1~2d,使细胞分布更为均匀)。2d后供移植修复SD大鼠坐骨神经缺损用。Microinject first (inject the mixed suspension of seed cells into the scaffold with a micro-sampler under a microscopic surgical microscope, with an interval of 5 mm, and inject 20-50 μl each time), and then infiltrate and inoculate (the mixed suspension of seed cells is evenly added dropwise) On the support, incubate in the culture dish in suspension for 4 hours), and then rotate the culture (fix the support in the rotating culture chamber and cultivate for 1-2 days to make the cell distribution more uniform). After 2 days, it was used for transplantation and repair of sciatic nerve defect in SD rats.
实施例2:Example 2:
1.组织工程化周围神经移植体修复SD大鼠坐骨神经缺损1. Repair of sciatic nerve defect in SD rats with tissue engineered peripheral nerve graft
切除成年雄性SD大鼠(已取其皮肤进行了毛囊NCSC的分离培养)一侧坐骨神经10mm,断端距离维持15mm,用显微外科技术将神经移植体套接坐骨神经断端;另一侧不做手术。动物存活9周。Cut off 10mm of sciatic nerve on one side of adult male SD rats (the skin of which has been taken for isolation and culture of hair follicle NCSC), and keep the distance between the stumps at 15mm, and use microsurgical techniques to connect the nerve graft to the stump of sciatic nerve; Operation. Animals survived for 9 weeks.
动物分组如下:自体神经移植组、组织工程化周围神经移植组(毛囊NCSC诱导分化的神经元样细胞和类施万细胞分别按1∶1、2∶1、3∶1的比例植入)、诱导性组织工程神经移植组(仅植入毛囊NCSC诱导分化的类施万细胞)、犬去细胞神经基膜管支架移植组。每组5只动物,其中自体神经移植组所切除的坐骨神经长15mm,并用此段神经原位移植修复缺损神经。Animals were divided into groups as follows: autologous nerve transplantation group, tissue engineered peripheral nerve transplantation group (hair follicle NCSC-induced neuron-like cells and Schwann-like cells were implanted at a ratio of 1:1, 2:1, and 3:1, respectively), Inducible tissue engineered nerve transplantation group (only Schwann-like cells induced by hair follicle NCSC implantation), canine decellularized nerve basement membrane tube scaffold transplantation group. There were 5 animals in each group. The sciatic nerve excised in the autologous nerve transplantation group was 15mm long, and this segment of nerve was orthotopically transplanted to repair the defective nerve.
2.功能恢复的评估2. Evaluation of Functional Recovery
(1)参照deMedinaceli法(参见Exp Neurol,1982,77∶634)测量大鼠后爪印迹,计算出坐骨神经功能指数。(1) According to the de Medinaceli method (see Exp Neurol, 1982, 77:634), measure the rat hind paw imprint, and calculate the sciatic nerve function index.
(2)以平步梯形仪检测各组动物的触板次数,以评估其功能恢复情况。触板次数越少,功能恢复越好。(2) The number of times the animals in each group touched the plate was detected with a flat step trapezoidal instrument to evaluate their functional recovery. The fewer touches, the better the recovery of function.
(3)手术9周后在再生神经近侧端实施电刺激,在远侧端记录其动作电位,同时观察腓肠肌的收缩情况;测量小腿三头肌的重量和肌力。(3) After 9 weeks of operation, electrical stimulation was performed at the proximal end of the regenerated nerve, and the action potential was recorded at the distal end, while the contraction of the gastrocnemius muscle was observed; the weight and muscle strength of the triceps calf were measured.
研究发现,组织工程化周围神经移植组的功能恢复优于诱导性组织工程神经移植组和空支架移植组,与自体神经移植组相接近。其中效果最佳的实验组是毛囊NCSC诱导分化的神经元样细胞和类施万细胞按1∶1的比例种植组。The study found that the functional recovery of the tissue-engineered peripheral nerve transplantation group was better than that of the induced tissue-engineered nerve transplantation group and the empty scaffold transplantation group, and was similar to that of the autologous nerve transplantation group. Among them, the experimental group with the best effect was the implantation group of hair follicle NCSC-induced neuron-like cells and Schwann-like cells at a ratio of 1:1.
SEQUENCE LISTINGSEQUENCE LISTING
<110>中国人民解放军第二军医大学<110> The Second Military Medical University of the Chinese People's Liberation Army
<120>组织工程化周围神经移植体及其制备方法<120> Tissue engineered peripheral nerve graft and preparation method thereof
<130>说明书,权利要求书<130> specification, claims
<160>2<160>2
<170>PatentIn version 3.1<170>PatentIn version 3.1
<210>1<210>1
<211>9<211>9
<212>PRT<212>PRT
<213>人工序列<213> Artificial sequence
<400>1<400>1
Cys Asp Pro Gly Tyr Ile Gly Ser ArgCys Asp Pro Gly Tyr Ile Gly Ser Arg
1 51 5
<210>2<210>2
<211>10<211>10
<212>PRT<212>PRT
<213>人工序列<213> Artificial sequence
<400>2<400>2
Cys Gln Ala Ala Ser Ile Lys Val Ala ValCys Gln Ala Ala Ser Ile Lys Val Ala Val
1 5 101 5 10
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710039573 CN101066472B (en) | 2007-04-18 | 2007-04-18 | Tissue engineered peripheral nerve graft and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710039573 CN101066472B (en) | 2007-04-18 | 2007-04-18 | Tissue engineered peripheral nerve graft and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101066472A CN101066472A (en) | 2007-11-07 |
CN101066472B true CN101066472B (en) | 2010-05-19 |
Family
ID=38879253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200710039573 Expired - Fee Related CN101066472B (en) | 2007-04-18 | 2007-04-18 | Tissue engineered peripheral nerve graft and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101066472B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102181396B (en) * | 2011-03-24 | 2012-10-24 | 中国人民解放军第三军医大学第三附属医院 | Method for inducing neural stem cells to be directionally differentiated into sensory neurons in vitro |
CN106421912A (en) * | 2016-10-13 | 2017-02-22 | 中山大学 | Preparation and application of matrix acellular nerve scaffold |
CN110249047A (en) * | 2016-11-14 | 2019-09-17 | 纪念斯隆-凯特琳癌症中心 | Use the drug discovery method for the schwann cell for being originated from stem cell |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003070465A (en) * | 2001-08-31 | 2003-03-11 | Keio Gijuku | Schwann cell culture method |
JP2005168760A (en) * | 2003-12-10 | 2005-06-30 | Gunze Ltd | Support for regenerative medicine, support for revascularization, support for nerve regeneration and treatment method |
-
2007
- 2007-04-18 CN CN 200710039573 patent/CN101066472B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003070465A (en) * | 2001-08-31 | 2003-03-11 | Keio Gijuku | Schwann cell culture method |
JP2005168760A (en) * | 2003-12-10 | 2005-06-30 | Gunze Ltd | Support for regenerative medicine, support for revascularization, support for nerve regeneration and treatment method |
Also Published As
Publication number | Publication date |
---|---|
CN101066472A (en) | 2007-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Transplantation of bone marrow stromal cells for peripheral nerve repair | |
Su et al. | Induction of endometrial mesenchymal stem cells into tissue-forming cells suitable for fascial repair | |
KR100907248B1 (en) | Volume replacement method of body by transplantation of differentiated young fat cells and biodegradable polymer | |
Komiyama et al. | A novel technique to isolate adult Schwann cells for an artificial nerve conduit | |
Goel et al. | Effect of bone marrow-derived mononuclear cells on nerve regeneration in the transection model of the rat sciatic nerve | |
de Souza Lucena et al. | Experimental considerations concerning the use of stem cells and tissue engineering for facial nerve regeneration: a systematic review | |
CN101668848A (en) | Pluripotent autologous stem cells from oral mucosa and methods of use | |
Pan et al. | Acellular nerve grafts supplemented with induced pluripotent stem cell-derived exosomes promote peripheral nerve reconstruction and motor function recovery | |
WO2006001428A1 (en) | Method of inducing the differentiation of amnion-origin cells and utilization of the same | |
AU2007352480B2 (en) | New stem cell lines, their application and culture methods | |
Wu et al. | Tissue engineering in female pelvic floor reconstruction | |
Jiang et al. | Tissue-engineered rhesus monkey nerve grafts for the repair of long ulnar nerve defects: similar outcomes to autologous nerve grafts | |
CN102335459A (en) | Hair follicle reconstruction method based on hair follicle stem cells and fibroblast | |
US20140271616A1 (en) | Compositions And Methods For Mesenchymal And/Or Chondrogenic Differentiation Of Stem Cells | |
US20100022003A1 (en) | Therapeutic cell medicine comprising skin tissue derived stem cell | |
CN108546674A (en) | Pre-stimulation stem cell and its preparation method and application | |
Applegate et al. | Whole-cell bioprocessing of human fetal cells for tissue engineering of skin | |
CN101066472B (en) | Tissue engineered peripheral nerve graft and preparation method thereof | |
CN102161981B (en) | Method for jointly inducing bone marrow mesenchymal stem cells into sweat gland cells by recombinant protein | |
CN111514374A (en) | A method for promoting cartilage repair based on tissue engineered cartilage constructed by co-culture system | |
CN101318031A (en) | Preparation method of neuronal tissue engineered peripheral nerve | |
KR20080071656A (en) | Method of manufacturing artificial artificial skin using cultured hair follicle cells | |
CN112755250A (en) | Tissue engineering peripheral nerve tissue and preparation method thereof | |
AU2005202726B2 (en) | Bone regeneration | |
WO2024037293A1 (en) | Cellular matrix nerve graft for repairing peripheral nerve injury and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100519 Termination date: 20160418 |
|
CF01 | Termination of patent right due to non-payment of annual fee |